Rasna Therapeutics Inc. (RASP) Financial Statements (2023 and Earlier)

Company Profile

Business Address 420 LEXINGTON AVENUE
NEW YORK, NY 10170
State of Incorp. NV
Fiscal Year End September 30
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2021
9/30/2020
9/30/2019
9/30/2018
3/31/2017
6/30/2016
6/30/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments111450434,04900
Cash and cash equivalents111450434,04900
Receivables 11423885  
Other undisclosed current assets341876766  
Total current assets:4533723474,20000
Noncurrent Assets
Property, plant and equipment 0257  
Intangible assets, net (including goodwill)  2,9592,9592,959  
Goodwill  2,7232,7232,723  
Intangible assets, net (excluding goodwill)  236236236  
Other undisclosed noncurrent assets  1,9131,9131,91300
Total noncurrent assets: 04,8744,8784,87900
TOTAL ASSETS:45334,9465,2259,07900
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,5161,6361,5911,422903544
Accounts payable 952864720549 4
Accrued liabilities61668472770235452 
Taxes payable     2 
Other undisclosed accounts payable and accrued liabilities900    0 
Debt370165   9 
Due to related parties561550550550625107
Other undisclosed current liabilities260 265137   
Total current liabilities:2,7072,3502,4052,1091,5287311
Noncurrent Liabilities
Liabilities, other than long-term debt   11   
Deferred tax liabilities, net11   
Other undisclosed noncurrent liabilities  3    
Total noncurrent liabilities:  311   
Other undisclosed liabilities 357     
Total liabilities:2,7072,7082,4092,1201,5287311
Stockholders' equity
Stockholders' equity attributable to parent(2,663)(2,675)2,5373,1067,551(72)(11)
Common stock696969696833
Additional paid in capital20,71219,91519,78019,41216,7414848
Accumulated deficit(23,444)(22,658)(17,312)(16,375)(9,258)(123)(62)
Total stockholders' equity:(2,663)(2,675)2,5373,1067,551(72)(11)
TOTAL LIABILITIES AND EQUITY:45334,9465,2259,07900

Income Statement (P&L) ($ in thousands)

9/30/2021
9/30/2020
9/30/2019
9/30/2018
3/31/2017
6/30/2016
6/30/2015
Operating expenses(248)(5,429)(915)(4,070)(4,535)(62)(17)
Operating loss:(248)(5,429)(915)(4,070)(4,535)(62)(17)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
 79(29)(4)101  
Interest and debt expense91(41)(28)    
Loss from continuing operations before equity method investments, income taxes:(157)(5,391)(972)(4,074)(4,434)(62)(17)
Other undisclosed income from continuing operations before income taxes 4128    
Loss from continuing operations before income taxes:(157)(5,350)(944)(4,074)(4,434)(62)(17)
Income tax expense (benefit)26138(2)628  
Income (loss) before gain (loss) on sale of properties:104(5,347)(936)(4,076)(3,806)(62)(17)
Other undisclosed net loss(889)      
Net loss:(785)(5,347)(936)(4,076)(3,806)(62)(17)
Other undisclosed net loss attributable to parent    (628)  
Net loss available to common stockholders, diluted:(785)(5,347)(936)(4,076)(4,434)(62)(17)

Comprehensive Income ($ in thousands)

9/30/2021
9/30/2020
9/30/2019
9/30/2018
3/31/2017
6/30/2016
6/30/2015
Net loss:(785)(5,347)(936)(4,076)(3,806)(62)(17)
Comprehensive loss, net of tax, attributable to parent:(785)(5,347)(936)(4,076)(3,806)(62)(17)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: